Given its ability to inhibit NF-κB signaling and induce an AhR-like functional signature, DMF supplementation in MS patients or addition of DMF ex vivo during differentiation can reverse MS monocytes’ proinflammatory signature, leading to more powerful tolDCs. This evidence concerns the gene NFKB1 and myeloid sarcoma.